News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

SNO 2017: Toca 511/FC Lead to Durable Responses in IDH1 Wildtype and Mutant Recurrent High-Grade Glioma

Al's Comment:

 The cool thing is that all of the responders still do not have a recurrence.  Way too early to be talking about a cure - and it is a small group of patients,  but  ALL of the IDH1 mutant high grade glioma patients had a complete response, which has lasted 2-4 years so far. 


Posted on: 12/02/2017

SNO 2017: Toca 511/FC Lead to Durable Responses in IDH1 Wildtype and Mutant Recurrent High-Grade Glioma

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites



Musella Foundation For Brain Tumor Research & Information, Inc